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The viral immediate-early transactivator Rta/Orf50 is necessary and sufficient to initiate Kaposi’s sarcoma-
associated herpesvirus/human herpesvirus 8 (KSHV/HHV-8) reactivation from latently infected cells. Since
Rta/Orf50 is conserved among all known gamma-2-herpesviruses, we investigated whether the murine gamma-
68-herpesvirus (MHV-68) and rhesus monkey rhadinovirus (RRV) homologs can functionally substitute for
KSHV Rta/Orf50. (i) Our comparison of 12 KSHV promoters showed that most responded to all three
Rta/Orf50proteins, but three promoters (vGPCR, K8, and gB) responded only to the KSHV Rta/Orf50 trans-
activator. Overall, the activation of KSHV promoters was higher with KSHV Rta than with the RRV and
MHV-68 Rta. (ii) Only the primate Rta/Orf50 homologs were able to interfere with human p53-depedent
transcriptional activation. (iii) Transcriptional profiling showed that the KSHV Rta/Orf50 was more efficient
than it’s homologs in inducing KSHV lytic transcription from the latent state. These results suggest that the
core functionality of Rta/Orf50 is conserved and independent of its host, but the human protein has evolved
additional, human-specific capabilities.
Kaposi’s sarcoma-associated herpesvirus/human herpesvirus
8 (KSHV/HHV-8) is convincingly associated with Kaposi’s
sarcoma (KS) and the AIDS-associated lymphoproliferative
disorders, primary effusion lymphoma and multicentric Castle-
man’s disease (reviewed in reference 1). Animal models rep-
resent important systems for the study of the biology and
pathogenesis of KSHV, in light of the fact that the human virus
replicates poorly in culture. Currently, there are two animal
model systems that are widely used to investigate KSHV biol-
ogy based on their sequence relatedness to KSHV. These in-
clude murine gamma-68-herpesvirus (MHV-68) and rhesus
monkey rhadinovirus (RRV), both of which replicate to high
titers in tissue culture and are capable of establishing persistent
infection in their respective hosts (2, 14, 37, 55, 57). In order to
increase the applicability of these systems, it is important to
compare key genes (and potential therapeutic targets) en-
coded by these three viruses.
Lytic replication of herpesviruses follows an ordered cascade
of gene expression. Immediate-early (alpha) proteins are tran-
scribed first, followed by early (beta) and finally late (gamma)
proteins. The three gamma-2-herpesviruses, KSHV, RRV, and
MHV-68, all encode a viral immediate-early transactivator
protein named Rta/Orf50 in a similar genomic location. More-
over, all three rhadinovirus Rta transcripts share a similar
architecture. They comprise two exons separated by an intron,
which is essentially composed of the Orf49 gene (10, 34, 50,
57). In each case, splicing of the two exons and excision of the
intervening intron results in a single, major Rta transcript, but
there are also many bicistronic alternatively spliced Rta-con-
taining transcripts. The KSHV Rta/Orf50 protein is indispens-
able for reactivation from latency. It also activates a variety of
cellular and viral promoters. Introduction of KSHV Rta/Orf50
alone into latently infected cells is sufficient for initiating the
entire viral lytic cascade (19, 34, 50), while a dominant-nega-
tive Rta/Orf50 mutant protein is able to abolish KSHV repli-
cation (35). The Rta/Orf50 protein in the related murine rhadi-
novirus MHV-68 fulfills the same function (57). KSHV Rta/
Orf50 can transactivate a number of KSHV early promoters by
several different mechanisms. (i) Purified Rta/Orf50 binds di-
rectly to its consensus sequence in the KSHV KbZIP/K8, Mta/
Orf57, Nut-1/Pan, and viral interleukin-6 (vIL-6) promoters (5,
8, 13, 33, 49). (ii) It can interact with RBP-jk, and this inter-
action positively regulates the Nut-1, Orf57, ssB, and thymi-
dine kinase (TK) promoters (31). (iii) It autoregulates its own
promoter via the Oct-1 transcription factor. (iv) It may also aid
in Sp-1-mediated and general transcription (9, 21, 43, 48, 53,
59). It also induces the K5 promoter (24). Studies with RRV
Rta/Orf50 by our laboratory and others have demonstrated
that this protein can dramatically transactivate the RRV R8,
and RRV Orf57 promoters (10, 32). The KSHV Rta/Orf50 was
also able to transactivate these RRV early promoters, suggest-
ing that the functionality between the RRV and KSHV Rta
proteins is conserved (10). KSHV encodes other immediate-
early proteins, namely, Orf45 and Orf K8/KbZIP, which also
contribute to lytic replication. However, unlike Rta/Orf50,
none of these proteins alone can induce KSHV lytic reactiva-
tion from latently infected primary effusion lymphoma cells
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(50, 51). Recent evidence suggests that these proteins are pri-
marily involved with the regulation of cellular pathways that
pave the way for complete viral lytic replication in more re-
strictive cell types (26, 56, 61).
The Rta/Orf50 proteins of KSHV, RRV, and MHV-68 are
homologous and show a high degree of sequence similarity at
the amino acid level. In order to determine whether this se-
quence similarity translated into a conservation of function, we
analyzed the ability of the KSHV, RRV, and MHV-68 Rta/
Orf50 proteins to activate a set of KSHV immediate-early,
early, and late gene promoters in epithelial, endothelial, and
B-cell lines. Here we report that all three Rta/Orf50 proteins
were able to activate several KSHV promoters. However, the
RRV and MHV-68 Rta/Orf50 proteins were significantly de-
pressed in their ability to activate KSHV promoters compared
to the KSHV Rta/Orf50 protein. In particular the KSHV K8,
vGPCR, kaposin, and gB promoters only responded to KSHV
Rta/Orf50, but not to any of its homologs. In addition, only
KSHV and RRV Rta/Orf50, but not the murine homolog,
were able to inhibit p53’s transactivation function, a property
of Rta/Orf50 that has been described by Gwack et al. (22).
Finally, we compared the ability of the three proteins to reac-
tivate the KSHV lytic cycle when transfected into BCBL-1
cells, which are latently infected with KSHV. We found that
although the KSHV, RRV, and MHV-68 Rta/Orf50 proteins
could induce the complete KSHV reactivation program as
previously defined (16, 27, 40, 44), RRV and MHV-68 Rta/
Orf50 were less effective than KSHV Rta/Orf50.
Alignment of the rhadinovirus Rta/Orf50 proteins. The
three Rta/Orf50 proteins of KSHV, RRV, and MHV-68 are
well conserved, raising the possibility that the transactivation
functions of the Rta/Orf50 proteins are likewise conserved
among this group of proteins. Figure 1A depicts the alignment
of the amino acid sequences encoded by the Rta/Orf50 pro-
teins of KSHV, RRV, and MHV-68, which was performed
using the ClustalW program. The amino acid similarity be-
tween KSHV and RRV Rta/Orf50 is 55%, the amino acid
similarity between KSHV and MHV-68 Rta/Orf50 is 43%,
and the amino acid similarity between RRV Rta/Orf50 and
MHV-68 Rta/Orf50 is 47%. Amino acids 1 to 380 are con-
served in all three proteins, followed by a more deletion-prone
region and two more conserved blocks at amino acids 500 to
570 and 615 to 660. Expression of truncated versions of the
KSHV Rta/Orf50 protein revealed that DNA binding was me-
FIG. 1. Three Rta/Orf50 proteins of the gamma-2-herpesvirus family. (A) ClustalW alignment of the three Rta/Orf50 proteins of KSHV, RRV,
and MHV-68. Conserved amino acids are indicated by stars, and similarly charged residues are indicated by a semicolon. (B) Western blot of
Rta/Orf50 protein expression after transient transfection into 293 cells. KSHV Rta/Orf50 was detected with an antibody against Rta/Orf50, and
RRV and MHV-68 Rta/Orf50 proteins were epitope tagged and detected with antibodies against either an AU1 or Flag tag, respectively.
(C) Western blot of the three Rta/Orf50 proteins in the four different cell lines. Lanes: 1 and 5, BJAB B cells; 2 and 6, BCBL-1 B cells; 3 and 7,
SLK endothelial cells; 4 and 8, 293 epithelial cells. One hundred-fifty micrograms of total cell extract from the BJAB, BCBL, and SLK cells and
80 g of cell extract from the 293 cells were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blots were performed with
either an AU1 antibody to detect RRV Orf50, Flag antibody to detect MHV-68 Orf50, or Rta antibody (K. Ueda) to detect KSHV Orf50.
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diated by the amino-terminal 272 amino acids (33), which is
consistent with our alignment in Fig. 1A, where this region is
conserved among all three Rta/Orf50 rhadinovirus proteins.
Figure 1B depicts a Western blot of the three Rta/Orf50 pro-
teins expressed in 293 cells. All three proteins exhibit a higher
apparent molecular weight than that predicted by their amino
acid sequence. This is consistent with prior reports that showed
that the KSHV and MHV-68 proteins are posttranslationally
modified by phosphorylation (8, 31, 34, 47, 49, 57).
Comparison of KSHV, RRV, and MHV-68 Rta/Orf50 activ-
ities on a panel of KSHV promoters. In order to evaluate the
impact of the different Rta/Orf50 proteins with regard to the
KSHV viral life cycle, we compared the ability of the KSHV,
RRV, and MHV-68 transactivators to activate KSHV promot-
ers in three relevant cell lines: KSHV-negative SLK endothe-
lial cells, KSHV-negative BJAB B lymphocytes, and 293 epi-
thelial cells. KSHV has been shown to be tropic for both B cells
and endothelial cells and has also previously been shown to
infect and replicate in 293 epithelial cells (17, 41, 42, 60). The
KSHV promoters we used have been previously described (28,
31, 33–35). These include the immediate-early/early promoters
KSHV Rta/Orf50, K8, and Mta/Orf57. The set of delayed early
promoters included promoter regions for KSHV Nut-1 (also
called Pan), viral G-protein-coupled receptor (vGPCR), DNA
binding protein (DBP), vIL-6, TK, kaposin (or K12), and DNA
polymerase (POL). The set of late gene promoters included
those for glycoprotein B (gB) and assembly protein (AP). To
control for experimental variation, transfections were per-
formed in duplicate and repeated five times in each cell line.
To control for transfection efficiency, the results were normal-
ized using a -galactosidase expression vector, which was co-
transfected with the Rta expression plasmids and all the lucif-
erase reporter plasmids in each experiment. The same cell
extracts were used to measure the -galactosidase activity and
luciferase activity of each sample. To control for similar ex-
pression levels of all three Rta/Orf50 proteins, the three gam-
ma-2-herpesvirus Rta/Orf50 cDNAs were all expressed from a
pcDNA3 expression vector (Invitrogen). The three Rta/Orf50
proteins showed similar levels of expression in each cell line
when expressed from this vector (Fig. 1C). To determine the
effect of Rta/Orf50 on the different promoters, transactivation
by Rta/Orf50 was calculated as fold activation compared to
pcDNA3 vector alone. This normalization procedure allowed
us to compare the relative effect of the three Rta/Orf50 pro-
teins on all promoters in all cell lines.
BJAB is an Epstein-Barr virus- and KSHV-negative B-cell
line. BJAB cells were electroporated with the promoter con-
structs described above and one of the three Rta/Orf50 expres-
sion plasmids. Table 1 depicts the transcriptional activation
seen with these constructs in BJAB B lymphocytes. (i) Pro-
moter activity, which was measured in luciferase units for each
of the plasmids and normalized to -galactosidase activity, is
represented as fold activation over the pcDNA3 vector control
(see also Fig. 2A). (ii) To compare the efficiency of the three
Rta/Orf50 proteins, the activation of each KSHV promoter by
the KSHV Rta/Orf50 transactivator was set at 100%, and the
ability of RRV and MHV-68 transactivators to activate the
same promoter was calculated as a percentage of the activity
seen with the KSHV Rta/Orf50 protein. Although the RRV
and MHV-68 proteins could transactivate the KSHV promot-
ers of all three groups of immediate-early, early, and late
genes, overall transactivation efficiencies were lower than that
seen with the autologous KSHV Rta/Orf50 transactivator. In
BJAB cells, KSHV Rta/Orf50 was able to transactivate the
immediate-early promoter K8 significantly, whereas the other
two Rta/Orf50 homologs failed to do so to any significant
degree above background. This was also true for the delayed
early promoters, vGPCR and kaposin, and the gB promoter.
This phenotype is consistent with a report by Chang et al. (4)
and KSHV array analysis (27, 40) that found gB mRNA and
the gB promoter fragment used here exhibit viral early kinet-
ics. The late AP promoter was not significantly activated by any
of the Rta/Orf50 proteins. Both primate Rta/Orf50 proteins
could activate the KSHV Nut-1 promoter, whereas the MHV-
68 Rta/Orf50 protein was not able to significantly transactivate
this promoter.
An identical set of experiments were performed in 293 ep-
ithelial cells. 293 epithelial cells have been previously shown to
support KSHV infection in vitro (17, 41, 42, 60). We trans-
fected the aforementioned promoter constructs into these cells
along with the KSHV, RRV, or MHV-68 Rta/Orf50 expression
plasmids as described above. Promoter activity was measured
by luciferase units for each of the plasmids and depicted as fold
activation over the pcDNA3 vector control (Table 1 and Fig.
2B). As can be seen in Table 1, although the RRV and
MHV-68 proteins could transactivate all three classes of pro-
moters, their efficiencies were lower compared to the autolo-
gous KSHV protein, as was the case in BJAB cells. In 293 cells,
the KSHV Rta/Orf50 protein was able to transactivate the
immediate-early/early K8 promoter significantly, whereas the
other Rta/Orf50 transactivators could not. This was also true
for the delayed early promoter, vGPCR, and the late gB pro-
moter. However, in 293 epithelial cells, the RRV Rta/Orf50
transactivator was able to moderately activate the Nut-1, DBP,
kaposin, TK, and AP promoters, whereas MHV68 Rta/Orf50
did not significantly activate these promoters.
SLK is a KS tumor-derived endothelial cell line that is KSHV
negative (25, 36, 41). It was of particular interest to measure
promoter activity in these cells since KSHV can infect endo-
thelial cells in vitro and KS lesions are comprised of a large
number of infected endothelial cells. Furthermore, KSHV Rta/
Orf50 can induce KSHV lytic transcription experimentally in in
vitro KSHV- infected SLK cell populations (R. Renne and D.
Dittmer, unpublished observation). We transfected the afore-
mentioned promoter constructs into these cells along with the
KSHV, RRV, or MHV-68 Rta/Orf50 expression plasmids as
described above. Table 1 and Fig. 2C depicts the transcrip-
tional activation seen with these constructs in SLK endothelial
cells. Once again, the promoter activity for each construct is
represented as fold activation over the pcDNA3 vector control.
As can be seen in Table 1, although the RRV and MHV-68
proteins could transactivate all three classes of promoters,
their transactivation efficiencies were lower than that seen with
the autologous KSHV protein, a pattern similar to the results
we obtained in BJAB and 293 cells. Furthermore, the KSHV
Rta/Orf50 protein was able to transactivate the immediate-
early/early promoter, K8, significantly, whereas the two other
Rta/Orf50 transactivators could not. This was also true for the
delayed early promoter, vGPCR, as well as the kaposin pro-
moter and the gB promoter. In SLK cells, the RRV Rta/Orf50
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transactivator was able to moderately activate the Nut-1 pro-
moter whereas MHV-68 Rta/Orf50 did not significantly acti-
vate this promoter.
In summary, we tested a panel of 12 KSHV promoters in
three different cell lines that are relevant for KSHV tropism/
infection, which include B cells, endothelial cells, and epithe-
lial cells. In all three cell lines, the KSHV viral transactivator
activated the autologous KSHV promoter significantly, as has
been previously described (3, 6, 7, 10, 19, 30, 33, 34, 39, 43, 46,
49, 51, 57, 59, 61). These studies provide for the first simulta-
TABLE 1. Transactivation of KSHV promoters by rhadinovirus Rta/Orf50 proteinsa
Cells and promoters
Activation (fold) % of KSHV activity
Class
KSHV RRV MHV-68 KSHV RRV MHV-68
BJAB cells
Immediate early/early
Orf50-p 17  5 10  4 24  1 100 60 147 All
K8-p 90  8 5  0 2  0 100 5 2 Human
Orf57-p 54  0 20  1 19  1 100 37 36 All
Delayed early
Nut1-p 39  3 29  0 2  0 100 74 6 Primate
GPCR-p 49  8 7  0 3  1 100 14 7 Human
DBP-p 9  1 3  1 3  0 100 27 33 All
vIL-6-p 22  8 13  3 5  1 100 57 22 All
TK-p 10  2 6  0 4  1 100 65 39 All
Kaposin-p 27  4 2  2 1  0 100 8 5 Human
POL-p 6  0 6  0 4  1 100 90 57 All
Late
gB-p 28  2 2  0 3  0 100 8 9 Human
AP-p 2  0 2  0 1  0 NA NA NA None
HEK293
Immediate early/early
Orf50-p 5  1 5  0 8  0 100 100 150 All
K8-p 161  10 19  1 5  1 100 12 3 Human
Orf57-p 31  0 26  1 50  4 100 84 161 All
Delayed early
Nut1-p 393  8 99  8 5  0 100 25 1 Primate
GPCR-p 386  10 27  0 21  0 100 7 6 Human
DBP-p 78  26 15  1 5  0 100 20 6 Primate
vIL-6-p 171  10 48  2 39  1 100 28 23 Human
TK-p 96  1 37  1 6  1 100 38 6 Primate
Kaposin-p 34  1 22  1 3  1 100 64 10 Primate
POL-p 5  0 63  1 7  1 100 1163 124 All
Late
gB-p 159  12 32  1 20  1 100 20 13 Human
AP-p 4  0 7  0 1  1 100 205 21 Primate
SLK cells
Immediate early/early
Orf50-p 12  2 8  3 27  10 100 68 230 All
K8-p 100  15 17  1 3  1 100 17 3 Human
Orf57-p 67  3 36  3 30  1 100 54 45 All
Delayed early
Nut1-p 46  10 22  7 1  0 100 49 2 Primate
GPCR-p 46  8 2  0 2  0 100 5 5 Human
DBP-p 11  3 5  2 2  1 100 42 19 All
vIL-6-p 18  1 6  1 7  1 100 35 38 All
TK-p 14  2 10  0 3  1 100 72 23 All
Kaposin-p 29  1 5  3 1  1 100 17 3 Human
POL-p 5  0 6  0 9  2 100 120 192 All
Late
gB-p 15  1 3  0 1  0 100 23 9 Human
AP-p 1  0 1  0 2  0 NA NA NA None
a Shown is a summary of the results obtained by cotransfection experiments between KSHV, RRV, and MHV-68 Rta/Orf50 proteins and a panel of KSHV promoters
fused to a luciferase reporter gene. All promoter activity was normalized to -galactosidase activity and is shown as fold induction over empty expression vector and
as percent activity relative to KSHV Rta/Orf50.
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neous comparison of primate Rta/Orf50 proteins. In contrast
to KSHV, the RRV and MHV-68 Rta/Orf50 transactivators
were notably reduced in their ability to transactivate this panel
of KSHV promoters. In this set of KSHV promoters, the over-
all response patterns to KSHV Rta/Orf50 were similar in
BJAB B-cells and SLK endothelial cells (Fig. 2). Surprisingly,
in 293 cells the Mta/Orf57 promoter was less responsive to
KSHV Rta/Orf50 relative to the Nut-1 promoter, while the
opposite was true in SLK and BJAB cells. This suggests that
the compositions of host factors that mediate Rta/Orf50’s ef-
fects differ between 293 and the other two cell lines and un-
derscores the need to conduct transactivation studies in mul-
tiple cell lines. Neither the RRV nor MHV-68 Rta/Orf50
proteins were able to activate the KSHV K8, vGPCR GPCR,
or the gB promoter. This suggests that some interactions be-
tween human cellular transcription factors and KSHV Rta/
Orf50 are not evolutionary conserved but are required for at
least this subset of KSHV promoters. We would predict that a
subset of basic transcription factors that interacts with KSHV
Rta/Orf50 (20) includes proteins that would not interact with
either the RRV or MHV-68 Rta/Orf50 proteins. The regula-
tion of vGPCR, K8, and gB promoters by KSHV Rta/Orf50
appears to be unique to the human virus and may explain some
aspects of its biology.
Rta/Orf50’s interaction with p53 is restricted to the primate
viruses. KSHV Rta/Orf50 has been demonstrated to inhibit
p53’s transactivation function (23), which is independent of
Rta/Orf50’s specific DNA-binding function. We compared the
ability of MHV-68 and RRV Rta/Orf50 transactivators to in-
hibit p53’s transactivation function by using a well-established
p53-responsive element (58). As seen in Fig. 2D, only RRV
and KSHV Rta/Orf50 were able to interfere with human p53’s
transactivation function, but MHV-68 Rta/Orf50 could not.
This suggests that the interaction between the primate Rta/
Orf50 proteins and human p53 has evolved later during spe-
ciation. Similar to the interaction between the human papillo-
mavirus E6 proteins and p53 (45, 54), which can be interrupted
by slight amino acid variation between “high-risk” and “low-
risk” strains, the interaction between Rta/Orf50 and p53 also
shows high specificity.
Comparison of the genome-wide effects of KSHV, RRV, and
MHV-68 Rta/Orf50 proteins on KSHV reactivation. In order
to evaluate the impact of the different Rta/Orf50 proteins on
the KSHV life cycle, we analyzed the effect of expression of the
individual Rta/Orf50 proteins on KSHV reactivation from la-
tently infected BCBL-1 cells. KSHV Rta/Orf50 has previously
been shown to efficiently induce KSHV lytic replication in
these cells (34, 50, 51), and KSHV Rta/Orf50 alone is neces-
sary and sufficient to induce the latent to lytic switch. We
electroporated 107 BCBL-1 cells with 20 g of empty vector
pcDNA3 or the three different pcDNA3-Orf50 expression con-
structs along with 5 g of pEGFP plasmid (Clontech, Inc.).
Forty-eight hours postelectroporation, the cells were sorted
based upon GFP fluorescence. No cells were excluded based
on scatter, since KSHV reactivation in BCBL-1 cells induces a
blast phenotype, which changes the light scatter profile of the
cells. In independent experiments, between 5  103 and 10 
103 GFP-positive cells were sorted and mRNA was isolated,
reverse transcribed, and analyzed using our previously devel-
oped real-time quantitative reverse transcription-PCR (RT-
PCR) array for KSHV (12, 16). We previously showed that
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNA levels do not change upon KSHV reactivation in
BCBL-1 cells (16). We also tested several other cellular
mRNAs in this system, including those for actin, 18S rRNA,
and hypoxanthine phosphoribosyltransferase. These did not
change in response to KSHV reactivation (data not shown).
Since these mRNAs correlated with each other, as expected
based on prior studies (12, 16), we chose to normalize all data
based upon the level of GAPDH mRNA and subjected the
normalized data to statistical analysis (52). Figure 3A shows a
Treeview representation after hierarchical clustering of the
FIG. 2. Transactivation functions of KSHV, RRV, and MHV-68
Rta/Orf50. Panels A, B, and C depict the results of the transfection
data from Table 1 for BJAB, 293, and SLK cells, respectively. (D) In-
hibition of human p53 transactivation of a p53-responsive promoter/
luciferase construct in p53-negative (10)1 cells. Promoter activity was
measured as relative light units normalized to a cotransfected -galac-
tosidase promoter. The ability of all three Rta/Orf50 proteins to inhibit
p53 activity is quantified as a percentage of inhibition.
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data from cells sorted with a fluorescence-activated cell sorter
48 h after treatment (15). Overall, the repeat experiments
showed an identical pattern: relative to mock-treated cells,
KSHV Rta/Orf50 significantly induced the transcription of all
KSHV lytic mRNAs (indicated by the dark shade of gray) but
not cellular mRNAs or latency type I mRNAs. Electroporation
of an RRV or MHV-68 Rta/Orf50 expression plasmid also
induced KSHV transcription, but to a lesser degree than
KSHV Rta/Orf50. This could presumably have occurred due to
the nonhuman Rta/Orf50 proteins activating the KSHV Rta/
Orf50 promoter and thus initiating a complete, albeit delayed,
lytic replication cascade. Figure 3B shows the data from the
total culture at 72 h postelectroporation. Here data were also
normalized relative to mock-transfected cells as described in
references 12 and 16. Relative to mock-transduced cultures,
KSHV Rta/Orf50-transfected BCBL-1 cultures induced virtu-
ally all mRNAs, RRV Rta/Orf50-transfected cultures likewise
induced all mRNAs, but to a lesser degree. Consistently, for
every time point tested, MHV-68- Rta/Orf50-transfected BCBL
cells exhibited the least amount of induction at this time point.
At the 24-h time point, no significant differences in KSHV
transcription were observed in cells transfected with three Rta/
Orf50 homologs and cells transfected with a GFP expression
plasmid (data not shown).
As in our transfection experiments, we could discern genes
that were responsive to the Rta/Orf50 viral transactivator of
any species. We also identified genes that were only activated
by KSHV Orf50/Rta. This is exemplified in Fig. 3C, which
shows the results of two independent experiments. Shown here
are the normalized (CTgapdh) values for a latent mRNA,
v-cyclin (vCYC), and two early gene mRNA transcripts, Orf57/
Mta and vGPCR. In this representation, lower CT (change in
cycle threshold [CT]) values correspond to higher mRNA lev-
els on a logarithmic scale. As expected, v-cyclin mRNA was
unaffected by KSHV, RRV, or MHV-68 Rta/Orf50 as com-
pared to the vector-only-transfected BCBL-1 cells. We had
previously shown that the LANA promoter, which also drives
v-cyclin expression, is unaffected by KSHV Rta/Orf50 (28).
The mRNA for Mta/Orf57 is significantly induced by RRV or
MHV-68 Rta/Orf50 and even more so by KSHV Rta/Orf50 as
compared to the vector-transfected cells. In contrast, only the
KSHV Rta/Orf50 protein, but not the RRV or MHV-68 Rta/
Orf50 protein, induces the mRNA for vGPCR, as evidenced by
a 5-U decrease in CT (corresponding to a 1.85- or 19-fold
difference). The pattern of transactivation of KSHV mRNA
transcripts in the context of the viral genome parallels the
pattern seen with the individual KSHV promoters, as shown in
Table 1.
Figure 3D shows a plot of the levels of induction (CT) by
RRV or MHV-68 Rta/Orf50 for each of the KSHV genes (y
axis) relative to the induction that was achieved by KSHV Rta/
Orf50 alone (x axis). The values are represented on a logarith-
mic scale, to allow for a more robust statistical analysis (18). As
can be gleaned from this two-dimensional representation, nei-
ther the MHV-68 nor RRV Rta/Orf50 proteins induced KSHV
lytic mRNAs to the levels seen after transfection of KSHV
Rta/Orf50 expression plasmid. However, both RRV Rta/Orf50
and MHV-68 Rta/Orf50 induced the complete KSHV reacti-
vation program. Although the RRV Rta/Orf50 protein could
activate KSHV promoters better than the MHV-68 protein in
both reporter assays (Table 1) and the viral microarray (Fig.
3A and B), the primate Rta/Orf50 protein was not dramatically
better at inducing KSHV reactivation as a whole than the
MHV-68 protein, as evidenced by their overlapping expression
profiles (Fig. 3D). This suggests a mechanism whereby
MHV-68 or RRV Rta/Orf50 cannot fully substitute for KSHV
Rta/Orf50 but may instead initiate lytic replication by inducing
the KSHV immediate-early promoters, such as the KSHV Rta/
Orf50 promoter. In this scenario, the rate-limiting step for
complete, ordered lytic replication may also be dependent on
the time postelectroporation of the BCBL-1 cells.
To validate our statistical analysis, we performed Gaussian
clustering using a second different, genetic optimization algo-
rithm with ArrayMiner 2.6 under Macintosh OsX (Optimal
Design, Inc., Brussels, Belgium). We analyzed the complete
data sets for these experiments followed by flow cytometry
sorting for each rhadinovirus Rta/Orf50 as well as vector con-
trol (595 data points after exclusion of some PCR failures).
The algorithm terminated with five essentially similar clusters
(data not shown), as well as genes that did not change expres-
sion upon electroporation. The latter group included the cel-
lular housekeeping mRNAs c-myc and hu-actin, as well as the
KSHV latent mRNAs for LANA and v-cyclin (not shown).
This is consistent with our prior observations, which found that
neither LANA mRNA nor the LANA promoter is activated
upon KSHV reactivation in BCBL-1 cells (11, 16, 28). All other
KSHV mRNAs were induced by KSHV Rta/Orf50 relative to
the vector. Four mRNAs that were most highly induced by
KSHV Rta/Orf50 relative to vector were the KSHV K2, K4,
Rta/Orf50, and K8 transcripts. RRV and MHV Rta/Orf50 also
induced KSHV lytic mRNAs but much less efficiently.
Summary. All herpesvirus lytic replication occurs in an or-
dered sequence of gene expression. Immediate-early mRNAs
are transcribed in the absence of de novo protein synthesis,
early mRNAs are activated by the immediate-early transacti-
vating factors, and late mRNA transcription is blocked by
inhibiting viral DNA replication. Once the immediate-early
protein(s) is made, this transcriptional cascade culminates in
capsid assembly, virion egress, and death of the host cell.
One question regarding the evolution of the gammaherpes-
FIG. 3. Ability of the three Rta/Orf50 proteins to reactivate KSHV from latently infected BCBL-1 cells. (A) “Heatmap” representation of
KSHV mRNA after transfection with KSHV, RRV, or MHV-68 Rta/Orf50 as determined by real-time quantitative RT-PCR (16). The three
leftmost panels represent mock-treated cells and two replicate experiments of sorted, Rta/Orf50-transfected cells after 48 h. (B) KSHV mRNA
levels in the total culture 72 h after transfection with KSHV, RRV, or MHV-68 Rta/Orf50. Darker shades of gray correspond to higher mRNA
levels on a log 2 scale. (C) Plots of three individual relative mRNA ( CT) levels selected from panel A for KSHV v-cyclin (CYC), Mta/Orf57,
and vGPCR on the vertical axis for each of the experiments on the horizontal axis. (D) mRNA levels ( CT) after electroporation with KSHV,
RRV, or MHV68 Rta/Orf50 on the horizontal axis relative to the mRNA levels after electroporation with KSHV Rta/Orf50.
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virus subfamily pertains to the degree of functional conserva-
tion that exists among the human, primate, and vole rhadino-
viruses. We find that the immediate-early Rta/Orf50 proteins
of KSHV, RRV, and MHV-68 are highly conserved in amino
acid sequence (Fig. 1), as well as in their ability to activate
relevant KSHV viral promoters (Fig. 2). KSHV Orf50 alone is
necessary and sufficient to induce KSHV lytic reactivation in
BCBL-1 cells (33–35, 50, 51). We demonstrate here that the
RRV and MHV-68 Rta/Orf50 protein can function similarly.
In addition, we found important qualitative as well as quanti-
tative differences among the three homologous proteins: Some
KSHV promoters (K8, vGPCR, gB, and kaposin) only respond-
ed to KSHV Rta/Orf50, but not to RRV or MHV-68 Rta/
Orf50, while other promoters responded to all three (Rta/
Orf50, Mta/Orf57, DBP, vIL-6, TK, Pol, and AP). This is not
unexpected since Rta/Orf50 has multiple modes of action. It
transactivates the Nut-1, Orf57, and K8 promoters by binding
directly to DNA (33, 47, 49), while other promoters may be
activated indirectly through protein-protein interactions. Inter-
estingly, we had previously observed that KSHV Rta activated
the RRV R8, Orf57, and gB promoters but only weakly acti-
vated the RRV v-IRF and Orf50 promoters (10).
In the context of latently infected BCBL-1 cells, addition of
KSHV Rta/Orf50 was sufficient to induce the complete lytic
transcription program, which agrees with a recent study by
Nakamura et al. (38). Extending their work, we found that KSHV
Rta/Orf50 was much better at inducing complete KSHV reac-
tivation than either the RRV or MHV-68 Rta/Orf50 homologs
(Fig. 3). This suggests that while either Rta/Orf50 homolog is
sufficient to induce KSHV reactivation, other KSHV immedi-
ate-early or early proteins, such as KbZIP/K8 (56, 61), Mta/
Orf57 (29), or Orf45 (61), cooperate with Rta/Orf50 to com-
plete the lytic cascade. We surmise that this cooperation is
species specific. The delayed replication kinetics in cells that
are transfected by RRV or MHV-68 Rta/Orf50 suggests that
enough KSHV Rta/Orf50 protein needs to accumulate in the
BCBL-1 cells to circumvent this species barrier and activate
complete lytic protein expression. Ultimately, mature KSHV
virions are produced in this system, regardless of which rhadi-
novirus Rta/Orf50 protein initiates the process.
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